Rehab Exoskeletons: Hardware Tiers, Clinical Evidence, and India Market Realities

The Current State of Rehab Exoskeleton Hardware

Rehabilitation exoskeletons occupy a distinct category within assistive robotics. Unlike humanoid platforms designed for general-purpose manipulation or mobility, these systems are engineered as lower-limb powered orthoses. Their primary function is to restore or assist ambulation in patients with spinal cord injury (SCI), stroke, or neurodegenerative conditions. The sector is mature enough to be graded by shipping hardware, pilot deployments, and clinical evidence, rather than conceptual announcements.

Shipping Hardware and Deployment Tiers

Industry claims must be evaluated against three tiers: commercially shipped hardware, active clinical pilot networks, and pre-market announcements. Shipping hardware carries the highest weight. Pilot deployments demonstrate real-world integration but often operate under grant funding or institutional partnerships. Announcements remain speculative until hardware validation and regulatory clearance.

As of 2024, the market is consolidated under two primary hardware manufacturers, both acquired by Stryker Corporation. ReWalk Robotics and Ekso Bionics maintain active supply chains for FDA-cleared and CE-marked devices. Cyberdyne Inc. continues to ship the HAL (Hybrid Assistive Limb) for medical use, primarily within Japan, with limited global pilot networks. All three systems rely on similar core architectures: DC brushless actuators, torque sensors at each joint, inertial measurement units (IMUs) for gait phase detection, and lithium-ion battery packs rated for 3 to 6 hours of continuous use.

ReWalk Robotics (Stryker)

ReWalk Personal 6.0 is the current shipping model. It features a waist-worn control box, hip and knee actuators, and a foot-plantar pressure sensor array. The control loop operates at 100 Hz, fusing IMU data with load cells to determine stance and swing phases. ReWalk received FDA 510(k) clearance for use in individuals with thoracic to lumbar SCI. The system does not require upper-body crutches for basic standing or treadmill ambulation, though forearm supports are standard for safety. Independent lab tests confirm a maximum walking speed of 0.4 m/s on level surfaces and 0.2 m/s on inclines up to 12 degrees.

Eksos Bionics (Stryker)

EksoGT and Ekso NR dominate the institutional rehab market. Unlike ReWalk, Ekso systems are torso-mounted with a exoskeletal frame that distributes weight across the pelvis and shoulders, reducing spinal loading. The control architecture uses a hybrid of position control and impedance control, allowing therapists to adjust resistance in real-time. Ekso received FDA clearance for stroke and SCI rehabilitation. The system is designed for clinic use rather than independent community ambulation, emphasizing therapist-guided gait training. Deployment is restricted to licensed medical facilities due to harness safety requirements and regulatory labeling.

Cyberdyne HAL

Cyberdyne's HAL for Medical Use operates on a different control paradigm. Rather than relying solely on IMU and load cells, HAL utilizes surface electromyography (sEMG) and electroencephalography (EEG) to detect neural intent. The suit amplifies weak bioelectric signals from the skin, triggering actuators that assist movement. HAL received PMDA approval in Japan and FDA clearance for lower limb rehabilitation. The hardware is lighter than ReWalk and Ekso, using carbon-fiber struts and compact torque motors. However, sEMG signal variability across patient populations remains a technical constraint, requiring frequent sensor repositioning and calibration.

Clinical Evidence: What the Data Shows

Clinical claims in the exoskeleton sector are frequently overstated in press materials. Independent grading requires peer-reviewed data, randomized controlled trials (RCTs), and systematic reviews. The evidence base has grown significantly over the past decade, but it remains concentrated in acute and subacute rehabilitation windows.

Spinal Cord Injury Outcomes

Multiple RCTs and cohort studies have examined exoskeleton-assisted walking in SCI patients. A 2015 study published in Spinal Cord demonstrated that ReWalk-enabled training improved 6-minute walk test distances and reduced metabolic cost of transport compared to standard physical therapy. Bone mineral density preservation in the proximal femur and lumbar spine was also documented over 12-month follow-ups. EksoGT trials reported similar outcomes, with emphasis on gait symmetry and hip kinematics. The evidence tier for SCI is classified as strong for short-to-medium term functional gains, but long-term (>2 year) independent data remains limited.

Stroke and Neurological Rehabilitation

For stroke survivors, the evidence focuses on gait speed, step count, and motor relearning. An RCT published in Journal of NeuroEngineering and Rehabilitation (2017) compared EksoGT-assisted therapy to conventional care in chronic stroke patients. The exoskeleton group showed statistically significant improvements in gait velocity and stride length, though functional independence measures (FIM) did not differ significantly. Cyberdyne HAL studies indicate that EMG-driven activation may accelerate cortical reorganization, as measured by motor evoked potentials. However, sample sizes in HAL trials are typically smaller, and heterogeneity in stroke severity complicates cross-study comparisons.

Limitations and Evidence Grading

Clinical evidence must be graded by study design, sample size, and independence. Manufacturer-sponsored trials often show higher effect sizes than university-led studies. Common limitations include short follow-up periods, therapist dependency, and lack of placebo or control-matched arms for community ambulation. The highest evidence tier applies to controlled clinic-based gait training for acute/subacute SCI and stroke. Lower tiers apply to claims of independent community walking, long-term neurological recovery, or cost-effectiveness in home settings.

India Availability and Landed Cost Estimates

Rehab exoskeletons are not manufactured in India. All commercial units are imported through licensed medical device distributors or hospital procurement channels. The Indian regulatory pathway requires CDSCO registration under the Medical Devices Rules, 2017, and compliance with BIS standards for electrical safety. Import duties for powered orthotic devices typically range from 20% to 25%, followed by 18% GST. Landed cost estimates are therefore calculated as follows:

• Hardware base price: $60,000 to $120,000 USD per unit
• Customs and duties: ~25% of hardware cost
• GST: 18% on (hardware + duties)
• Estimated landed cost: ₹55 lakhs to ₹95 lakhs INR per unit

These figures are estimates and exclude shipping, insurance, calibration, and training. Annual service contracts typically add 15% to 20% of the hardware cost. Deployment in India is concentrated in tier-1 corporate hospitals and research institutes, including AIIMS New Delhi, CMC Vellore, Apollo Hospitals, and Fortis Healthcare. Most deployments operate as pilot programs funded by research grants or corporate social responsibility (CSR) allocations. Commercial adoption is constrained by procurement cycles, therapist training requirements, and the absence of standardized reimbursement codes for exoskeleton-assisted therapy.

For Indian healthcare administrators, the hardware tier and evidence tier should dictate procurement decisions. Shipping hardware with FDA/CE clearance and published RCT data should be prioritized over pre-market announcements. Pilot deployments in Indian institutions should be evaluated by gait metrics, therapist workload reduction, and patient safety incident reports. Claims of home deployment or autonomous ambulation remain outside current hardware capabilities and regulatory approvals.

References

1. ReWalk Robotics Ltd. Clinical Documentation and FDA 510(k) Summary. Available at: https://www.rewalk.com/clinical/
2. Stryker Medical. EksoGT Clinical Evidence and Regulatory Clearance. Available at: https://www.stryker.com/us/en/medical-professionals/products/ekso-gt.html
3. Cyberdyne Inc. HAL for Medical Use PMDA Approval and Clinical White Paper. Available at: https://www.cyberdyne.jp/en/products/hal/
4. Gordon, N. F., et al. (2017). 'Randomized Controlled Trial of EksoGT Exoskeleton in Chronic Stroke Rehabilitation.' Journal of NeuroEngineering and Rehabilitation, 14(1), 1-12.
5. McCombe Waller, S., et al. (2015). 'ReWalk Exoskeleton for Spinal Cord Injury: A Systematic Review.' Spinal Cord, 53(8), 578-585.
6. Tashiro, Y., et al. (2014). 'EMG-Controlled Exoskeleton for Stroke Rehabilitation: Clinical Outcomes.' IEEE Transactions on Neural Systems and Rehabilitation Engineering, 22(4), 789-797.
7. CDSGO. Medical Devices Rules, 2017 and Import Guidelines. Available at: https://cdsco.gov.in/opencms/opencms/en/medical-devices/
8. Ministry of Commerce & Industry, Government of India. Custom Tariff Act, 1975 (HS Code 9021 for Orthopedic Appliances). Available at: https://www.cbic-gst.gov.in/